Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages e122-e124

  Johnson, Douglas B ^a   Saranga Perry, Vita ^a   Lavin, Patrick J M ^b   Bryan Burnette, W ^b   Clark, Stephen W ^b   Uskavitch, David R ^b   Wallace, Deborah E ^b   Dickson, Mark A ^c   Kudchadkar, Ragini R ^c   Sosman, Jeffrey A ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBOPLATIN; CHOLINERGIC RECEPTOR; CITALOPRAM; CORTICOTROPIN; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; LEVOTHYROXINE; METHYLPREDNISOLONE; PACLITAXEL; PREDNISONE; PYRIDOSTIGMINE; THYROTROPIN; TRAZODONE; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; AGED; ARTICLE; BLURRED VISION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CASE REPORT; CORTICOSTEROID THERAPY; CUTANEOUS MELANOMA; DIPLOPIA; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FREE THYROXINE INDEX; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN TISSUE; HYPERMETABOLISM; INGUINAL ADENOPATHY; INGUINAL LYMPH NODE; LEG DISEASE; LIMB WEAKNESS; LYMPH NODE DISSECTION; LYMPHADENOPATHY; METASTATIC MELANOMA; MITOSIS INDEX; MULTIPLE CYCLE TREATMENT; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYASTHENIA LIKE SYNDROME; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PLASMAPHERESIS; POPLITEAL ADENOPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; PTOSIS; RASH; SENTINEL LYMPH NODE BIOPSY; SKIN DEFECT; SUBCUTANEOUS NODULE; THYROTROPIN BLOOD LEVEL; WIDE EXCISION; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED; EPIDEMIOLOGY; FOLLOW UP; MELANOMA; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MELANOMA; METHYLPREDNISOLONE; MYASTHENIA GRAVIS; PLASMAPHERESIS; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84948464110     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.1683     Document Type: Article

References (24)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
3. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
4. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
5. Selby MJ, Engelhardt JJ, Quigley M, et al: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32-42, 2013
6. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
7. Weber JS, Ka hler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691-2697, 2012
8. Gaudy-Marqueste C, Monestier S, Franques J, et al: A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: A differential diagnosis for ipilimumab-induced colitis. J Immunother 36:77-78, 2013
9. Wilgenhof S, Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 22:991-993, 2011
10. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
11. Yi Q, Pirskanen R, Lefvert AK: Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J Neuroimmunol 42:215-222, 1993
12. Drachman DB: Myasthenia gravis. N Engl J Med 330:1797-1810, 1994
13. Jacob S, Viegas S, Leite MI, et al: Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 69:994-1001, 2012
14. Skeie GO, Apostolski S, Evoli A, et al: Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893-902, 2010
15. Gajdos P, Chevret S, Toyka K: Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev CD002275, 2002
16. Elovaara I, Apostolski S, van Doorn P, et al: EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893-908, 2008
17. Vincent A, Palace J, Hilton-Jones D: Myasthenia gravis. Lancet 357:2122-2128, 2001
18. Congeni JP, Kirkpatrick RB: Pegylated interferon induced myasthenia crisis: A case report. J Clin Neuromuscul Dis 14:123-125, 2013
19. Purvin V, Kawasaki A, Smith KH, et al: Statin-Associated myasthenia gravis: Report of 4 cases and review of the literature. Medicine (Baltimore) 85:82-85, 2006
20. Wang HB, Shi FD, Li H, et al: Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166:6430-6436, 2001
21. Wang XB, Kakoulidou M, Giscombe R, et al: Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: Effect of an AT-rich gene sequence. J Neuroimmunol 130:224-232, 2002
22. Fernandez-Mestre M, Sanchez K, Balbas O, et al: Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum Immunol 70:532-535, 2009
23. Wang XB, Pirskanen R, Giscombe R, et al: Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med 263:61-69, 2008
24. Gu M, Kakoulidou M, Giscombe R, et al: Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. Clin Immunol 128:374-381, 2008